期刊
CLINICAL MEDICINE
卷 16, 期 5, 页码 412-418出版社
ROY COLL PHYS LONDON EDITORIAL OFFICE
DOI: 10.7861/clinmedicine.16-5-412
关键词
Adrenal insufficiency; cobicistat; Cushing's syndrome; HIV; ritonavir
资金
- Janssen
- ViiV
- Bristol-Myers Squibb
- Merck Sharp Dohme
- Gilead
- MSD
- BMS
- Cipla
- Teva
- Mylan
- AbbVie
Ritonavir and cobicistat, used as pharmacokinetic enhancers in combination with some antiretrovirals (ARVs) for the treatment of HIV, are potent inhibitors of the CYP3A4 isoenzyme. Most glucocorticoids are metabolised via the CYP3A4 pathway and iatrogenic Cushing's syndrome (ICS), with possible secondary adrenal insufficiency (SAI), is a recognised complication following co-administration with ritonavir or cobicistat. A structured approach for identifying and managing potentially affected individuals has not been established. We systematically identified patients with ICS/SAI and found substantial heterogeneity in clinical practice across three large London HIV centres. While this significant drug interaction and its complications are now well-recognised, it is apparent that there is no standardised approach to management or guidance for the general physician. Here we describe the management of ICS/SAI in our current practice, review the available evidence and suggest practice recommendations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据